Penpulimab is under clinical development by Akeso and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase II drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Penpulimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Penpulimab is a monoclonal antibody with antineoplastic activity. It is formulated as solution for intravenous route of administration. Penpulimab is indicated for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma (CHL) after at least second-line systemic chemotherapy treatment. Penpulimab is under development for the treatment of recurrent, and metastatic cervical cancer, relapsed and refractory Hodgkin lymphoma, solid tumors including nasopharyngeal carcinoma, hepatocellular carcinoma, recurrent or metastatic colorectal cancer (second and third line), recurrent squamous cell carcinoma of the head and neck, recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma, metastatic urothelial carcinoma, gastrointestinal pancreatic neuroendocrine tumor, chest cancer, head and neck non-squamous cell cancer, metastatic head and neck non-squamous cell cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, oral cavity (mouth) cancer, undifferentiated thyroid cancer, small cell lung cancer, recurrent or metastasis pleural mesothelioma and thymic cancer, squamous and non-squamous non-small cell lung cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, esophageal squamous-cell carcinoma, hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) colorectal cancer, pancreatic carcinoma, cholangiocarcinoma and glioblastoma multiforme. It is administered through intravenous route. The therapeutic candidate acts by targeting programmed cell death protein 1 (PD-1). It is developed based on antibody analytical platform.
Akeso is a clinical-stage biopharmaceutical company that focus on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also provides kangfang integrated development platform (ACE Platform) which covers all drug R & D, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China
For a complete picture of Penpulimab’s drug-specific PTSR and LoA scores, buy the report here.